A protein called PU.1 plays a central role in the deposition of connective tissue during fibrosis, according to new research. The findings also suggested that blocking PU.1 may be a therapeutic strategy for pulmonary fibrosis and other fibrotic disorders. The study, “PU.1 controls fibroblast polarization and…
Scores of events are afoot worldwide to mark Feb. 28, Rare Disease Day 2019. The activities aim to raise awareness about rare diseases and the millions of people — estimates run as high as 350 million — they are thought to impact. Across countries, patients, caregivers and advocates will paint faces, wear…
Evotec and Galapagos will work together to develop a strategy to target fibrosis affecting several organs, the companies announced. The collaboration will focus on the development of small molecules designed to specifically target a new fibrosis biomarker identified and validated with Evotec’s proprietary platforms for fibrotic diseases…
A new online platform that pulmonary fibrosis (PF) patients, their friends, family, and caretakers to connect and get information about the disease, was launched recently by the Pulmonary Fibrosis Foundation (PFF) and Responsum Health. The service is free and its purpose is to offer PF patients access to trusted…
Canada’s SQI Diagnostics and the University Health Network (UHN) will work together to advance the development and approval of new rapid protein assays and a point-of-care (POC) diagnostic device to help surgeons assess the viability of lungs and other organs for transplant. This could represent an important step…
Elderly patients with idiopathic pulmonary fibrosis (IPF) have high morbidity and mortality, and experience a variety of comorbidities both before and after receiving their diagnosis, a study finds. The findings of the study, “Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data,” were published in…
The U.S. Food and Drug Administration (FDA) has cleared the way for X-Rx’s idiopathic pulmonary fibrosis (IPF) therapy candidate X-165 to move into the first clinical tests. The FDA approved X-Rx’s…
Results of a Phase 2b clinical trial suggest actigraphy as a relevant tool to detect meaningful clinical changes in patients with pulmonary hypertension (PH) associated with interstitial lung disease (PH-ILD) when treated with Bellerophon Therapeutics’ product INOpulse. PH-ILD includes PH patients with idiopathic pulmonary fibrosis (PH-IPF). The…
Treatment of idiopathic pulmonary fibrosis (IPF) with Esbriet (pirfenidone) increased five-year survival, and also resulted in less decline in lung function at two years, according to a real-life study from the Czech Republic. The findings also revealed that a specific measure of lung function called diffusing lung capacity…
He’s a musician and a clothing designer. He’s a published author. He’s a professional scuba-diving instructor — and he has an intense passion for underwater shark photography. In fact, Noah Greenspan is anything but your typical New York pulmonary physical therapist. Since 1998, Greenspan has been running the Pulmonary Wellness…
Get regular updates to your inbox.
